Table 3 HIV TDR-associated mutations identified among different subtypes/year in treatment-naïve Beijing MSM
PI | PI mutations | NRTI | NRTI mutations | NNRTI | NNRTI mutations | Total | |
|---|---|---|---|---|---|---|---|
Subtype | |||||||
CRF01_AE | 14.07% (19/135) | L10I/V(14/19) V11I(2/19) L33F(2/19) M46L(2/19) A71L(1/19) | 1.48% (2/135) | L74I(1/2) V75L(1/2) | 8.15% (11/135) | V106I(1/11) V179D/E(9/11) G190E(1/11) | 23.70% (32/135) |
CRF07_BC | 19.35% (12/62) | L10I(1/12) L33I(1/12) Q58E(2/12) A71T/V(8/12) | 0 | — | 1.61% (1/62) | E138G(1/1) | 20.97% (13/62) |
Subtype B | 22.72% (5/22) | L10I(1/5) A71T/V(5/5) | 0 | — | 31.81% (7/22) | V106I(5/7) , V179E(2/7) | 54.54% (12/22) |
Year | |||||||
2011 | 4.77% (1/21) | L10I(1/1) | 0 | — | 9.52% (2/21) | V106I(2/2) | 14.29% (3/21) |
2012 | 17.24% (22/126) | L10I/V(8/22) V11I(2/22) L33I/F(3/22) M46L(2/22) Q58E(1/22) A71T/V(6/22) | 2.63% (2/126) | L74I(1/2),V75L(1/2) | 11.1% (14/126) | V106I(4/14) E138G(1/14) V179D/E(8/14) G190E(1/14) | 29.37% (37/126) |
2013 | 17.11% (13/76) | L10I/V(5/13) Q58E(1/13) A71T/V(8/22) | 0 | — | 5.26% (4/76) | V179D(4/4) | 22.37% (17/76) |
Total | 16.14% (36/223) | 0.89% (2/223) | 8.52% (19/223) | 25.56% (57/223) | |||